Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ibrutinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK known ✓ | Q06187 | 14/20 | 1.00 |
| ▸ | EGFR | P00533 | 9/20 | 1.00 |
| ▸ | BMX | P51813 | 5/20 | 1.00 |
| ▸ | ITK | Q08881 | 4/20 | 1.00 |
| ▸ | TEC | P42680 | 3/20 | 1.00 |
| ▸ | HCK | P08631 | 3/20 | 1.00 |
| ▸ | SRC | P12931 | 3/20 | 1.00 |
| ▸ | BLK | P51451 | 3/20 | 1.00 |
| ▸ | TXK | P42681 | 2/20 | 1.00 |
| ▸ | LYN | P07948 | 2/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 2/20 | 1.00 |
| ▸ | NUDT5 | Q9UKK9 | 2/20 | 1.00 |
| ▸ | JAK3 | P52333 | 2/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | SLC22A3 | O75751 | 1/20 | 1.00 |
| ▸ | LATS1 | O95835 | 1/20 | 1.00 |
| ▸ | NUDT14 | O95848 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ibrutinib SCHEMBL201641 | 1.00 | BTK (1.00) | BTKEGFRBMXITKTEC | |
| Ibrutinib SCHEMBL2244870 | 1.00 | BTK (1.00) | BTKEGFRBMXITKTEC | |
| Ibrutinib SCHEMBL201859 | 1.00 | BTK (1.00) | BTKEGFRBMXITKTEC | |
| Ibrutinib SCHEMBL2244865 | 1.00 | BTK (1.00) | BTKEGFRBMXITKTEC | |
| SCHEMBL21428758 | 0.98 | BTK (0.95) | BTKEGFRBMXITKTEC | |
| SCHEMBL200391 | 0.95 | BTK (1.00) | BTKEGFRBMXITKTEC | |
| SCHEMBL200392 | 0.95 | BTK (1.00) | BTKEGFRBMXITKTEC | |
| SCHEMBL201548 | 0.95 | BTK (1.00) | BTKEGFRBMXITKTEC | |
| Ibrutinib SCHEMBL16887867 | 0.95 | BTK (0.93) | BTKEGFRBMXITKTEC | |
| SCHEMBL1613606 | 0.93 | EGFR (0.90) | BTKEGFRBMXITKTEC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1570 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729054-A1 | CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR | Pharmacyclics LLC (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4203942-B1 | IBRUTINIB FOR USE IN TREATING COCAINE USE DISORDER AND RELATED CONDITIONS | UNIV EMORY (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260062417-A1 | CRYSTALLINE FORMS OF A BRUTONS TYROSINE KINASE INHIBITOR | PHARMACYCLICS LLC (US) | 2026-03-05 | — | — | US | claimed |
| EP-2854859-B1 | CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR | PHARMACYCLICS LLC (US) | 2026-02-25 | — | — | EP | claimed |
| US-20250197404-A1 | SYNTHESIS OF A BRUTON'S TYROSINE KINASE INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2025-06-19 | — | — | US | claimed |
| US-20250127781-A1 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | PHARMACYCLICS, INC. | 2025-04-24 | — | — | US | claimed |
| US-20240409545-A1 | CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR | PHARMACYCLICS LLC (US) | 2024-12-12 | — | — | US | claimed |
| CN-118161618-A | Combination product comprising a Bcl-2 inhibitor or a Bcl-2/Bcl-xL inhibitor and use thereof | 苏州亚盛药业有限公司 | 2024-06-11 | — | — | CN | claimed |
| US-20240158400-A1 | SYNTHESIS OF A BRUTON'S TYROSINE KINASE INHIBITOR | PHARMACYCLICS LLC (US) | 2024-05-16 | — | — | US | claimed |
| US-20240065971-A1 | METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2024-02-29 | — | — | US | claimed |
| US-20100041677-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-02-18 | — | — | US | claimed |
| US-20100022561-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-01-28 | — | — | US | claimed |
| US-20100004270-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-01-07 | — | — | US | claimed |
| EP-2081435-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | Pharmacyclics, Inc. (US) | 2009-07-29 | — | — | EP | claimed |
| US-20090181987-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2009-07-16 | — | — | US | claimed |
| US-7514444-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2009-04-07 | — | — | US | claimed |
| US-20080139582-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-06-12 | — | — | US | claimed |
| US-20080108636-A1 | compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are told | PHARMACYCLICS, INC. (US) | 2008-05-08 | — | — | US | claimed |
| WO-2008039218-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-03-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062417-A1 | CRYSTALLINE FORMS OF A BRUTONS TYROSINE KINASE INHIBITOR | BTK, SYK, LYN | BTK 1/4885EGFR 261/4885BMX 34/4885 |
| US-20100022561-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | BTK 1/4885EGFR 836/4885BMX 11/4885 |
| US-20100004270-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | BTK 1/4885EGFR 836/4885BMX 11/4885 |
| US-20100041677-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | BTK 1/4885EGFR 836/4885BMX 11/4885 |
| US-20240065971-A1 | METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, BCL6, BCL6B | BTK 1/4885EGFR 1443/4885BMX 19/4885 |
| US-20240409545-A1 | CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR | BTK, SYK, LCK | BTK 1/4885EGFR 745/4885BMX 29/4885 |
| US-20090181987-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LCK, LYN | BTK 1/4885EGFR 728/4885BMX 11/4885 |
| US-20240158400-A1 | SYNTHESIS OF A BRUTON'S TYROSINE KINASE INHIBITOR | BTK, ABL1, LYN | BTK 1/4885EGFR 846/4885BMX 22/4885 |
| US-20080108636-A1 | compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are told | BTK, LCK, LYN | BTK 1/4885EGFR 703/4885BMX 23/4885 |
| US-20080139582-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | BTK, LCK, LYN | BTK 1/4885EGFR 1536/4885BMX 35/4885 |
| US-20250127781-A1 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) | BTK, LYN, SYK | BTK 1/4885EGFR 1644/4885BMX 18/4885 |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | BTK, LCK, LYN | BTK 1/4885EGFR 1550/4885BMX 32/4885 |
| US-20250197404-A1 | SYNTHESIS OF A BRUTON'S TYROSINE KINASE INHIBITOR | BTK, ABL1, LYN | BTK 1/4885EGFR 833/4885BMX 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.